Our panel members shared their thoughts about the impact of the pandemic. Over 1500 healthcare professionals and patients took part of our study.
*Scroll through the infographics to see all results

TAVR matches open-heart surgery durability in low-risk patients, as PARTNER 3 trial seven-year data confirm lasting valve performance.

Mesothelioma trial finds blocking miteochondrial enzym and enzyme in tumour cells controlled disease progression in 67% of patients.

Severe fatty liver disease may be eased as MASH treatment improves gut health, offering a promising new approach beyond the liver.